<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528059</url>
  </required_header>
  <id_info>
    <org_study_id>DongFang</org_study_id>
    <secondary_id>FNSP2009Y0039</secondary_id>
    <nct_id>NCT01528059</nct_id>
  </id_info>
  <brief_title>Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes</brief_title>
  <official_title>A Prospective Randomised Study Comparing Billroth II With Roux-en-Y Reconstruction After Radical Distal Subtotal Gastrectomy for Gastric Cancer Comorbid With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>feng Zheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiamen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric bypass improves glycemic levels in type 2 diabetes. However, the efficacy may be
      varied by different gastric-small intestine reconstruction used in the procedure. There are
      reports that Roux en Y reconstruction may give a better result. The purpose of this study is
      to compare Roux en Y and Billroth II reconstruction in patients with gastric cancer comorbid
      with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes may cause severe complications such as nephropathy and retinopathy.
      Additionally, it is associated with increased risk for cardiovascular events and diseases.
      Surgical intervention with gastric bypass has been shown to attenuate glycemic levels in
      obese patient comorbid with type 2 diabetes. However, since gastric bypass is not a standard
      procedure, surgical protocol including stomach and small intestine reconstruction may be
      varied. The investigators and others have found that stomach and small intestine
      reconstruction may affect the efficacy of diabetic treatment. In this study, the
      investigators will compare the efficacy of Billroth II and Roux en Y reconstruction on
      glycemic control in stomach cancer patients with type 2 diabetes. Both Billroth II and Roux
      en Y are used in stomach-small intestine reconstruction after subtotal gastrectomy. No
      differences in postoperative outcomes and quality of life have been reported in Billroth II
      and Roux en Y reconstruction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Fasting and postprandial glycemic levels, HbA1C
Number of anti-diabetic drugs
Dosage of anti-diabetic drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional status assessment</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Body mass index
Anthropometric analysis
Plasma concentrations of albumin, pre‚Äêalbumin, transferrin,and CRP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Billroth II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After stomach resection, the remnant stomach is connected to the jejunum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux en Y</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stomach-small intestine reconstruction</intervention_name>
    <description>Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes</description>
    <arm_group_label>Billroth II</arm_group_label>
    <arm_group_label>Roux en Y</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with Type 2 diabetes

          2. Diagnosed with gastric cancer

        Exclusion Criteria:

          1. Type 1 diabetes

          2. Unresectable cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Wang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongfang Hospital, Xiamen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Wang, M.D</last_name>
    <phone>13805019453</phone>
    <email>flyfishwang@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhongdong Zhou, M.D</last_name>
    <phone>13705038043</phone>
    <email>fzptwk@21cn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DongFang Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Wang, M.D</last_name>
      <phone>13805019453</phone>
      <email>flyfishwang@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ZhongDong Zhou, M.D</last_name>
      <phone>13705038043</phone>
      <email>fzptwk@21cn.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yu Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xiamen University</investigator_affiliation>
    <investigator_full_name>feng Zheng</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastric bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

